Studies of Phospholipase A2 as a new target for treatment of bronchial asthma

点击翻译按钮获取中文摘要

Cytosolic phospholipase A_2 (PLA_2) is the rate-limiting enzyme involved in the conversion of membrane phospholipids to arachidonic acid (AA) and lysophospholipids, which are readily metabolized to inflammatory mediators such as leukotrienes, thromboxane and platelet-activation factor. It has been recognized that receptor antagonists of leukotrienes or thronboxane are effective for treatment of bronchial asthma. To inhibit cPLA2 thus might be more effective than using leukotrienes or thronboxane receptor antagonist on treatment of bronchial asthma. We previously reported that cPLA2 regulates adhesion of human eosinophils to ICAM-1 or VCAM-1, and that inhibition of cPLA2 blocked eosinophil migration to lung tissue and antigen-induced airway hyperresponsiveness. In this study we investigated whether activity and quantitatition of cPLA2 in eosinophils from patients with asthma is more excessive than its from healthy donors.Both AA release and cPLA2 activity from patients with asthma by 1□M FMLP were greater than its from healthy donors significantly. Quantitation of cPLA2 is 0.36±0.13 ng/10^6 cells from healthy donors and 0.52±0.17 ng/10^6 cells from patients with asthma(p=0.0285)